
Auteur M. SALMINEN
|
Documents disponibles écrits par cet auteur (3)

L. WIESSING ; B. GUARITA ; I. GIRAUDON ; BRUMMER-KORVENKONTIO H. ; M. SALMINEN ; COWAN S. A. | 2008
Dans Eurosurveillance (Vol.13, n°21, 22 May 2008) Article : PériodiqueENGLISH : The human immunodeficiency virus (HIV) epidemic among injecting drug users (IDUs) shows different developments in different parts of the European region. In the countries of the European Union (EU) and the European Free Trade Associa[...]
S. J. M. HAHNE ; I. K. VELDHUIJZEN ; L. WIESSING ; T. A. LIM ; M. SALMINEN ; M. J. VAN DE LAAR | 2013
Dans BMC Infectious Diseases (Vol.13, n°181, 18 April 2013) Article : PériodiqueBACKGROUND: Treatment for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is improving but not benefiting individuals unaware to be infected. To inform screening policies we assessed (1) the hepatitis B surface antigen (HBs[...]
G. J. MACARTHUR ; E. VAN VELZEN ; N. E. PALMATEER ; J. KIMBER ; A. PHARRIS ; V. HOPE ; A. TAYLOR ; K. ROY ; E. ASPINALL ; D. GOLDBERG ; T. RHODES ; D. HEDRICH ; M. SALMINEN ; M. HICKMAN ; S. J. HUTCHINSON | 2014
Dans International Journal of Drug Policy (Vol.25, n°1, January 2014) Article : PériodiqueBACKGROUND: Injecting drug use is a major risk factor for the acquisition and transmission of HIV and Hepatitis C virus (HCV). Prevention of these infections among people who inject drugs (PWID) is critical to reduce ongoing transmission, morbid[...]